To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
42 Current news about the topic alnylam
rss
Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics
05-08-2004
Alnylam Pharmaceuticals, Inc. and Hybridon, Inc. ( announced that they have entered into an agreement providing Alnylam with an exclusive license to Hybridon's rights to target Vascular Endothelial Growth Factor (VEGF) for ocular indications with RNA interference molecules (RNAi). Hybridon ...
Alnylam Grants RNAx License to Key Patent in RNA Interference
28-01-2004
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that its German affiliate, Ribopharma AG, has granted RNAx GmbH a non-exclusive license to provide research services under a fundamental patent in RNA interference (RNAi). The licensed patent is the first ...
Netmeeting
